We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02337686
Recruitment Status : Active, not recruiting
First Posted : January 14, 2015
Last Update Posted : January 19, 2018
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : April 2019
  Estimated Study Completion Date : April 2019